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ABSTRACT 
This study investigates a new method of converting a crystalline drug to its 
amorphous form and studying the effect this conversion has on the solubility of 
the drug. The physical form of the drug is of great importance in the process of 
taking a drug molecule from its discovery to its formulation into an acceptable 
dosage form. For oral solid dosage forms, the physical state of the drug molecule 
influences various important parameters including bioavailability and stability. 
Bioavailability in tum is governed by factors like dissolution and solubility, which 
can be altered to give desired results. A review of the various methods involved 
in solid state modifications is provided to enable the reader to comprehend the 
importance and extensive applications of these techniques in the field of 
preformulation and pharmaceutical dosage form development. This study uses a 
poorly water-soluble drug, cefuroxime axetil, and determines the effects the 
treatment processes have on its solubility. The processes differ in that one renders 
the drug totally amorphous while the other disrupts the crystalline structure to an 
extent where it is in a partially crystalline state. The varied purposes of polymers 
used in this study have also been investigated. Polymers have been used to 
enhance solubility, act as impurities in the crystal structure, and in solution as 
crystallization inhibitors. The results of this study show that appropriate process-
polymer combinations can yield significant results for solubility enhancements. 
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SECTION I 
( 
l 
Introduction 
1.1 Solid States 
The existence of drugs and excipients m multiple physical forms (e.g. 
polymorphs, isomers) provides pharmaceutical scientists with an opportunity to 
select the preferred form(s) of the materials to be used in a formulation. This is 
very useful since critical properties, such as particle morphology and solubility, 
frequently vary between the different physical forms of a given active 
pharmaceutical ingredient (API) 1• The amorphous form of pharmacologically 
active materials has received considerable attention because, in theory, this form 
represents the most energetic solid state of a material, and thus it should provide 
the biggest advantage in terms of solubility and bioavailability2. Differences in 
the physical properties of various solid forms have an important effect on the 
processing of API's into drug products3, while differences in solubility may have 
implications on the absorption of the active drug from its dosage form4, by 
affecting dissolution rate and possibly the mass transport of the molecules. 
The most significant physical property of the solid state is the high degree of 
order in which substances (e.g. metals, minerals) usually exist. The structure may 
be crystalline and lattice-like or non-crystalline, such as in plastic, glass or gels, 
which are not lattice-like or only partly so. These latter materials do have, 
however, much more order than liquids and gases. These materials also have, in 
varying degrees, some plastic and elastic properties wherein some resistance to 
applied stresses exists, but when the stress reaches certain intensity, either flow or 
fracture ensues. Although different classifications exist, four major types of 
2 
( bonds hold solids together; the strong bonds impart higher melting points to drug 
substances. In order of decreasing strength, the bond types are metallic, ionic 
(salts), valence (diamond) and molecular (many organic compounds). Thus, in 
some solids, the atoms or molecules or ions may be arranged in a regularly 
repeating pattern (crystalline state), whereas other solids are considered non-
crystalline or amorphous if they do not have this characteristic of regularity5. 
1.2 Characteristics and Significance of the Crystalline and Amorphous States 
During the final stage of developing a new drug entity, a great deal of emphasis is 
placed on obtaining material of high purity and reproducibility in terms of its 
physical, chemical, and biological properties. Every effort is made to ensure a 
high degree of crystallinity, wherein the molecules have regular and well-defined 
molecular packing, and emphasis is also placed on whether or not the compound 
can exist in polymorphic or solvated crystal forms6. These forms can have 
different thermodynamic properties (e.g., melting temperature, vapor pressure, 
solubility), and knowledge of their existence is required to anticipate spontaneous 
changes in the properties of the solid during storage and/or handling of the 
material. It is also possible that upon isolation the material will be obtained in a 
fully or partially amorphous state7. 
Many compounds, especially complex organic molecules, will naturally occur or 
are capable of being manipulated to exist in more than one form as solids. Some 
of these forms are crystalline phases while others are meta-stable states where the 
compound is in a noncrystalline or molecularly dispersed form. Pharmaceutical 
3 
scientists have been making use of the differences in the physical chemical 
properties that exist between these various solid states to optimize drug delivery8. 
1.2.1 Crystalline Solids 
The crystalline state is thermodynamically favored for solids. It is characterized 
by the three-dimensional order of the molecules within its crystal lattice. The 
molecules are arranged in a pattern that minimizes the total energy of the crystal, 
both kinetic and potential. This usually results in a minimum amount of void 
space between the molecules, as there is a maximization of intermolecular contact 
(bonding). The packing arrangement for a compound will be a function of both 
its molecular shape and the chemical groups in the molecule involved in 
directional intermolecular bonding, e.g., hydrogen bonding, charge transfer 
interaction, and dipole-dipole interactions8. The structural units of crystalline 
solids, such as ice, sodium chloride, and menthol, are arranged in fixed geometric 
patterns or lattices. Crystalline solids, unlike liquids and gases, have definite 
shapes and an orderly arrangement of units. Gases are easily compressed, 
whereas solids, like liquids, are practically incompressible. Crystalline solids 
show definite melting points, passing rather sharply from the solid to the liquid 
state. The units that constitute the crystal structure can be atoms, molecules, or 
10ns. The sodium chloride crystal consists of a cubic lattice of sodium ions 
interpenetrated by a lattice of chloride ions, the binding force of the crystal being 
the electrostatic attraction of the oppositely charged ions. In diamond and 
graphite, the lattice units consist of atoms held together by covalent bonds. Solid 
4 
( carbon dioxide, and naphthalene form crystals composed of molecules as the 
building units. In organic compounds, the molecules are held together by Van der 
Waals forces, consisting of Keesam and London forces, which account for the 
various melting points of these crystals. Ionic and atomic crystals in general are 
hard and brittle and have high melting points9. 
1.2.2 Amorphous Solids 
The three-dimensional long-range order that normally exists m a crystalline 
material does not exist in the amorphous state, and the position of molecules 
relative to one another is more random as in the liquid state2 . These materials are 
referred to as glasses, noncrystalline, amorphous, and vitreous solids. Typically 
amorphous solids exhibit short-range order over a few molecular dimensions and 
have physical properties quite different from those of their corresponding 
crystalline states. The noncrystalline state is thermodynamically unstable and 
there will be a tendency to entropically drive these solids to a stable crystalline 
state. However, since the diffusional process is slow in the solid state, it is in 
many instances possible to isolate and make use of these materials in dosage 
forms . The free energy of these noncrystalline solids is much higher than that of 
their corresponding crystalline forms. As a result of its higher internal energy, the 
amorphous state should have enhanced thermodynamic properties relative to the 
crystalline state (e.g. , solubility, vapor pressure) and greater molecular motion. 
The high internal energy and specific volume can lead to enhanced dissolution 
and bioavailability10, but can also create the possibility that during processing or 
5 
storage the amorphous state may spontaneously convert back to the crystalline 
state 11 • 
Amorphous solids may be considered as supercooled liquids in which the 
molecules are arranged in a random manner similar to the liquid state. They 
differ from crystalline solids in that they tend to flow when subjected to sufficient 
pressure over a period of time, and they do not have definite melting points. An 
amorphous solid can also be defined with reference to a crystalline solid: similar 
to a crystalline solid, an amorphous solid may have short-range molecular order 
(i.e. in relationship to neighboring molecules); but unlike a crystalline solid, an 
amorphous solid has no long-range order of molecular packing or well-defined 
molecular conformation if the constituent molecules are conformationally 
flexible. Amorphous solids exist in many industrially important products, such as 
polymers, ceramics, metals, optical materials (glasses and fibers), foods and 
pharmaceuticals. In the case of pharmaceutical materials, the importance of 
amorphous solids stems from 12 : 
1. Useful properties. Amorphous solids have higher solubility, higher 
dissolution rate, and sometimes better compression characteristics than 
corresponding crystals. 
2. Instability. Amorphous solids are generally less stable physically and 
chemically than corresponding crystals. 
3. Common occurrence. Amorphous solids can be produced by standard 
pharmaceutical processes and are the common form of certain materials 
(e.g. proteins, peptides, some sugars and polymers). 
6 
( Amorphous solids may co-exist with and have the potential to convert to 
crystalline solids. The amorphous substances, however, cannot achieve their 
maximum theoretical solubility under practical experimental conditions because 
of the strong driving force for crystallization in the presence of the dissolution 
media '. Studies have been done where this problem has been avoided by adding 
crystallization inhibitors to the dissolution media13 ' 14, however, the use of such 
crystallization poisons is likely to alter the equilibrium solubility of the 
crystallized and/or amorphous forms. Amorphous solids exist widely in and 
impart special properties to pharmaceutical products. Given their instability, 
general strategies for stabilizing amorphous solids against crystallization and 
structural relaxation would be desirable 12 . 
Research aimed at stabilizing amorphous solids is multi-faceted, including: (i) the 
stabilization of labile biomolecules (e.g. proteins and peptides) through 
additives 15• 16• 17• 18, (ii) the prevention of crystallization of excipients that must 
remain amorphous for their intended functions 19' 20• 21 , (iii) the specification of 
appropriate storage temperatures to achieve acceptable shelf-life2' 11 ' 22, and (iv) 
the prevention of chemical degradation and microbial growth through anti-
oxidant, pH buffer, preservatives, etc. 
1.3 Solubilization by Solid-State Modification 
The solubility behavior of drugs remains one of the most challenging aspects in 
formulation development. With the advent of combinatorial chemistry and high 
7 
( throughput screerung, the number of poorly water-soluble compounds has 
dramatically increased and the formulation of poorly soluble compounds for oral 
delivery now presents one of the most frequent and greatest challenges to 
formulation scientists in the pharmaceutical industry23 . 
Together with permeability, the solubility behavior of a drug is a key determinant 
of its oral bioavailability. Consideration of the modified Noyes-Whitney 
equation24 provides some hints as to how the dissolution rate of even very poorly 
soluble compounds might be improved so that the limitations to oral availability 
can be minimized: 
dC = AD(Cs -C) 
dt h 
where, dC/dt is the rate of dissolution, A is the surface area available for 
dissolution, D is the diffusion coefficient of the compound, Cs is the solubility of 
the compound in the dissolution medium, C is the concentration of the drug in the 
medium at time t and his the thickness of the diffusion boundary layer adjacent to 
the surface of the dissolving compound. The main possibilities for improving 
dissolution according to this analysis are to increase the surface area available for 
dissolution by decreasing the particle size of the solid compound and/or by 
optimizing the wetting characteristics of the compound surface, to decrease the 
boundary layer thickness, to ensure sink conditions for dissolution and last but not 
the least, to improve the apparent solubility of the drug under physiologically 
relevant conditions. Of these possibilities, the most attractive option for 
8 
increasing the release rate is the improvement of the solubility through 
formulation approaches. Table 1 summanzes the vanous formulation and 
chemical approaches that can be taken to improve the solubility or to increase the 
available surface area for dissolution. 
Of the physical approaches, the use of polymorphs25, the amorphous form of the 
drug2, and complexation26' 27 have been widely reviewed. Decreasing the particle 
size of the compound by milling the drug powder theoretically results in an 
increase in the available area for dissolution, but in some cases the micronized 
powder tends to agglomerate, thereby at least partly negating the milling 
procedure. Presenting the compound as a molecular dispersion, on the other 
hand, combines the benefits of a local increase in the solubility and maximizing 
the surface area of the compound that comes in contact with the dissolution 
medium as the carrier dissolves. 
1.3.1 Crystal Defects 
The crystal lattice is generally regarded as a highly ordered structure that repeats 
itself in three dimensions. Guest molecules (impurities or additives), together 
with some crystallization solvent, are often incorporated into the host crystals 
during crystallization from solution. The guest molecules may be incorporated 
either in solid solution or in liquid inclusions, or by both mechanisms28 . Upon 
crystallization of crystals (the host) from the solution, impurities or additives (the 
guest molecules) in the crystallization medium are often found in the crystals at 
9 
I. Physical modifications 
Particle size 
Micronization 
N anosuspensions 
Modifications of the crystal habit 
Polymorphs 
Pseudopolymorphs (including solvates) 
Complexation/solubilization 
Use of surfactants 
Use of acceptable cyclodextrins 
Drug dispersion in carriers 
Eutectic mixtures 
Solid dispersions (non-molecular) 
Solid solutions 
II. Chemical modifications 
Soluble prodrugs 
Salts 
Table 1: Approaches to improve the solubility or to increase the available surface 
area for dissolution 
10 
various levels. The location of the guest molecule depends on the nature of the 
system, the treatment of the crystals upon harvesting, and the crystallization 
conditions, including concentrations of both the host and the guest in the 
crystallization medium, supersaturation of the host, and the degree of agitation29• 
30
• 
3 1
• 
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. This phenomenon may be termed 'doping' of the 'host' crystals by the 
' guest' molecules. Structurally, the guest may be closely related to the host, e.g. 
synthetic impurities29 ' 33 or chiral isomers34 ' 35' 36, or may significantly differ from 
the host, e.g. a macromolecular surfactant37 or the solvent itself38' 39 . However, 
even the most carefully prepared and grown crystals, such as those of many drug 
substances, inevitably contain defects, i.e. imperfections and residual impurities40 . 
Crystal defects can broadly be classified into point and lattice defects (see Figure 
1 ). Point defects are localized imperfections and are, in general , 
thermodynamically stable. They include vacancies (vacant sites in the crystal 
lattice caused by absence of atoms) and extra atoms (foreign or of same species) 
occupying interstitial or substitutional positions in the crystal lattice. Lattice 
defects include line defects or dislocations and grain boundaries, which are arrays 
of dislocations41. Dislocations are regions within the solid where the regularly 
repeating lattice array shows a discontinuity or distortion from the ideal alignment 
of units within the crystal. The atoms in this region are therefore not properly 
surrounded by neighbors. Since the imperfection is contained within a few 
atomic diameters of a line, it is called a line defect or dislocation42 . The nature 
and concentration of crystal defects are altered as a result of the stress prevailing 
during many pharmaceutical processing operations, such as drying, milling and 
11 
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Figure 1: Crystalline defects of various dimensionalities 
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( compression43• The imperfections may develop, wander, change their nature 
and/or disappear in the crystal lattice during processing10• 44 . Virtually all 
crystalline drug substances contain impurities which are incorporated into the 
crystal lattice during crystallization, or which are taken up by the crystal from the 
vapor phase, e.g. water. The impurity, a guest molecule, by the virtue of its 
different shape and electronic structure, interacts with the neighboring host 
molecules in a way, which is different from the interaction between a host 
molecule and the surrounding host molecules. Thus, the host molecules 
surrounding a guest molecule possess energies and occupy positions which are 
different from those of the host molecules surrounding another host molecule in a 
normal host lattice, to extents which depend on the difference between the shape 
and electronic structure of the impurity molecule and the host molecule40 . Thus, 
the incorporation of the impurity leads to a decrease in the overall symmetry of 
the crystal45 which has been demonstrated in organic solids by Weissinger -
Lewin et al46. 
Even in a crystal of 99.9% purity, one molecule in ten in any given direction is 
likely to be an impurity molecule40, perturbing the crystalline order of the lattice 
and increasing the lattice strain. As a result of the incorporation of an impurity, 
the increase in enthalpy of the solid itself due to the increased lattice strain may 
be partially offset by an increase in entropy, corresponding to the accompanying 
disorder, so that the corresponding increase in Gibbs free energy may not be 
large. However, because equilibrium properties such as solubility and solid 
13 
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reaction rates are exponential functions of Gibbs free energy, and because crystal 
disruption can arise relatively easily from the incorporation of impurity molecules 
and from the development of crystal imperfections, major effects on the 
physicochemical properties of solids may result43 . 
Crystals are always imperfect in some sense and these imperfections or defects 
can confer some important chemical and mechanical properties on crystalline 
materials41 . Crystal lattice imperfections, e.g. point defects and dislocations, 
develop during crystallization47 and have been found to exert major effects in 
pharmaceutical formulation and processing10. Crystal imperfections have also 
been shown to influence chemical reactivity6• 48 and dissolution rate41 . 
Consequently the bioavailability of a solid may be significantly increased by the 
presence of a high density of lattice imperfections. The process-induced changes 
in the solid-state properties often result in the batch-to-batch or lot-to-lot 
variations in the performance of pharmaceutical solid dosage forms, such as 
tablets and capsules. Digoxin represents a classical example of a drug whose 
dissolution rate and bioavailability can vary between wide limits if its crystal 
properties are not controlled49• 50• 51 . 
1.3.2 Solid Dispersions and Solid Solutions 
In 1961, a unique approach of solid dispersion to reduce the particle size and 
increase rates of dissolution and absorption was first demonstrated by Sekiguchi 
and Obi52 . They proposed the formation of a eutectic mixture of a poorly soluble 
drug with a physiologically inert, easily soluble carrier. The eutectic mixture was 
14 
( prepared by melting the physical mixture of the drug and the carrier, followed by 
a rapid solidification process. Upon exposure to aqueous fluids, the active drug 
was expected to be released into the fluids as fine, dispersed particles because of 
the fine dispersion of the drug in the solid eutectic mixture and rapid dissolution 
of the soluble matrix. The advantage of solid dispersion, compared with 
conventional capsule and tablet formulations, is shown schematically in Figure 
253. 
The term 'solid dispersion' can be defined as a dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state, prepared by the melting 
(fusion), solvent or melting-solvent method. The dispersion of a drug or drugs in 
a solid diluent or diluents by traditional mechanical mixing is not included in this 
category. The solid dispersions may also be called solid-state dispersions54 . 
Since the dissolution rate of a component from a surface is affected by the second 
component in a multiple component mixture, the selection of the carrier has an 
ultimate influence on the dissolution characteristics of the dispersed drug. 
Therefore, a water-soluble carrier results in a fast release of the drug from the 
matrix, and a poorly soluble or insoluble carrier leads to a slower release of the 
drug from the matrix . A simple 'eutectic mixture' consists of two compounds 
which are completely miscible in the liquid state but only to a very limited extent 
in the solid state (see Figure 3). When a mixture of A and B of composition Eis 
cooled, A and B crystallize out simultaneously, whereas when other compositions 
are cooled, one of the components starts to crystallize out before the other. Solid 
15 
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Figure 2: A schematic representation of the bioavailability enhancement of a 
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Figure 3: Phase diagram for a eutectic system 
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eutectic mixtures are usually prepared by rapid cooling of a melt of the two 
compounds in order to obtain a physical mixture of very fine crystals of the two 
components. When a mixture of composition E, consisting of a slightly soluble 
drug and an inert, highly water-soluble carrier, is dissolved in an aqueous 
medium, the carrier will dissolve rapidly, releasing very fine crystals of the drug52• 
55
. The large surface area of the resulting suspension should result in an enhanced 
dissolution rate and thereby improved bioavailability23. 
'Solid solutions ' are comparable to liquid solutions, consisting of just one phase 
irrespective of the number of components, and are made up of a solid solute 
dissolved in a solid solvent. It is often called a mixed crystal because the two 
components crystallize together in a homogenous one-phase system56. Solid 
solutions containing a poorly water soluble drug dissolved in a carrier with 
relatively good aqueous solubility achieve a faster dissolution rate than a eutectic 
mixture because the particle size of the drug in the solid solution is reduced to a 
minimum state, i.e., its molecular size, and the dissolution rate is determined by 
the dissolution rate of the carrier57 • By judicious selection of a carrier, the 
dissolution rate of the drug can be increased by up to several orders of magnitude. 
In addition to the reduction of the crystalline size, the following factors may 
contribute to the faster dissolution rate of a drug dispersed in these systems54, 
a) An increase in drug solubility may occur if the majority of its solid 
crystallites are extreme I y small 9. 
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( b) A solubilization effect by the carrier may operate in the microenvironrnent 
(diffusion layer) immediately surrouding the drug particle in the early 
stages of dissolution since the carrier completely dissolves in a short time. 
This was demonstrated by the faster dissolution rate of acetaminophen 
from its physical mixture with urea than that of the pure compound with 
comparable particle size58 . 
c) The absence of aggregation and agglomeration between fine crystallites of 
the pure hydrophobic drug may play a far more important role in 
increasing rates of dissolution and absorption than is presently recognized. 
Serious drawbacks of aggregation and agglomeration and lumping in the 
dissolution medium between pure drug particles are, however, rarely 
present in most solid dispersion systems because the individually 
dispersed particles are surrounded in a matrix of carrier particles. It must 
be emphasized that the aggregation and agglomeration of the solid 
dispersion powders may not significantly affect the dissolution of the 
drug, which can still disintegrate quickly due to the more rapid dissolution 
of the soluble carrier. This advantage of solid dispersion systems was 
demonstrated in the in vivo absorption59 of griseofulvin when dispersed in 
polyethylene glycol 6000 (10% w/w) and compressed into a hard tablet. 
The dissolution rate of the dispersed drug was found to be 25 times that of 
the pure drug. 
d) Excellent wettability and dispersibility of a drug from these systems, 
prepared with a water-soluble matrix result in an increased dissolution rate 
18 
of the drug in aqueous media. This is due to the fact that each single 
crystallite of the drug is very intimately encircled by the soluble carrier 
which can readily dissolve and cause the water to contact and wet the drug 
particle. As a consequence, a fine homogenous suspension of a drug can 
be easily obtained with minimum stirring52 . 
The methods that have been used to characterize solid dispersions are summarized 
in Table 2. Among these, the most important methods are thermoanalytical, X-
ray diffraction, infrared spectroscopy and measurement of the release rate of the 
drug. In addition to characterizing the solid dispersion, these methods can be 
used to differentiate between solid solutions (molecularly dispersed drug), solid 
dispersions in which the drug is only partly molecularly dispersed and physical 
mixtures of the drug and carrier23. 
1.3.3 Polymorphic Transformations 
Many drug substances can exist in more than one crystalline form with different 
space lattice arrangements. This property is known as polymorphism. The 
different crystal forms are called polymorphs. Crystalline polymorphs have the 
same chemical composition but different internal crystal structures and, therefore, 
possess different physicochemical properties. The different crystal structures in 
polymorphs arise when the drug substance crystallizes in different crystal packing 
arrangements and/or different conformations. The occurrence of polymorphism is 
quite common among organic molecules, and a large number of polymorphic drug 
19 
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Dissolution testing 
Thermoanalytical methods: differential thermoanalysis and hot stage 
rrucroscopy 
Calorimetric analysis of the solution or melting enthalpy for calculation 
of entropy change 
X-Ray diffraction 
Spectroscopic methods, e.g. IR spectroscopy 
Microscopic methods including polarization microscopy and scanning 
electron microscopy 
Table 2: Methods for the characterization of solid dispersions 
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compounds have been noted and catalogued60• 61 ' 62 ' 63 • Occasionally, a solid 
crystallizes, entrapping solvent molecules in a specific lattice position and in a 
fixed stoichiometry, resulting in a solvate or pseudopolymorph. If the 
incorporated solvent is water, the solvate is termed as a hydrate. Many solids may 
be prepared in a particular polymorphic form via appropriate manipulation of 
conditions of crystallization. These conditions include nature of the solvent, 
temperature, rate of cooling, and other factors . Because different crystalline 
polymorphs and solvates differ in crystal packing, and/or molecular conformation 
as well as in lattice energy and entropy, there are usually significant differences in 
their physical properties, such as density, hardness, tabletability, refractive index, 
melting point, enthalpy of fusion, vapor pressure, solubility, dissolution rate, other 
thermodynamic and kinetic properties and even color64 . The physical stability of 
any crystalline polymorph is dictated by its free energy. The most stable form 
under a given set of conditions is the form with the lowest free energy. All other 
solid-state modifications would in time transform to that particular crystalline 
phase8. The transformation rate of one polymorph to another, however, depends 
on the mobility of the molecules in the solid, the type of structural change that 
takes place, and environmental factors. If the transformation involves only a 
small degree of alteration in the intermolecular bonding, one could find a rapid 
conversion of a metastable form to the stable form. On the other hand, when a 
substantial difference in the packing arrangement exists between the two forms, 
the transformation can be extremely slow65 . Polymorphism has achieved 
significance in recent years owing to the fact that different polymorphs exhibit 
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different solubilities. In the case of slightly soluble drugs, this may affect the rate 
of dissolution. As a result, one polymorph may be more active therapeutically 
than another polymorph of the same drug. The polymorphic state of 
chloramphenicol palmitate has been shown to have a significant effect on the 
biological availability of the drug. It is essential, therefore to define and monitor 
the solid state of a drug substance. Occasionally, it may be necessary to search 
for a different polymorphic form to overcome stability, bioavailability, or 
processing problems. Differences in the dissolution rates and solubilities of 
different polymorphic forms of a given drug are used when absorption of the drug 
is dissolution rate limited66 . In such cases, a more soluble and faster dissolving 
form may be utilized to improve the rate and extent of bioavailability. 
1.4 Solid-State Characterization 
Many methods are available that can contribute information regarding the nature 
of a solid system. In many instances, a combination of two or more methods is 
required to study its complete picture. The analytical techniques used in this 
study will be discussed briefly in the following section. 
1.4.1 X-Ray Diffraction 
In 1912, Max Von Laue pointed out that if the wavelength of electromagnetic 
radiation became as small as the distance between atoms in the crystals, a 
diffraction pattern should result. Later it was found that the X-ray region has the 
right wavelength and a definite diffraction pattern was obtained for copper sulfate 
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( crystals. In essence, the crystal diffracts X-rays similar to a diffraction grating, 
whose plane diffracts ordinary light. The three-dimensional crystal functions like 
a series of plane gratings stacked one above the other5. For a single crystal the 
diffracted X-rays consist of a few lines; with powder, due to a random distribution 
of crystals, the diffraction pattern consists of a series of concentric cones with a 
common apex on the sample. The atoms in a crystal possess the power of 
diffracting the X-ray beam. Each substance scatters the beam in a particular 
diffracting pattern, producing a fingerprint for each atomic crystal or molecule. 
Powder X-ray diffraction analysis is employed for characterization of crystalline 
structure. It has been used to determine the existence of polymoprhic forms of 
many substances. It is a very important and efficient tool in studying the physical 
nature of solids. 
1.4.2 Differential Scanning Calorimetry (DSC) 
Thermal analysis is a technique in which a physical property of a substance is 
monitored as a function of controlled temperature increase. Modern thermal 
analytical methods can measure weight loss on heating, melting points, heat and 
energy of transitions and changes in form, in dimensions or in the viscoelastic 
properties of the substance. They find wide application in material 
characterization, purity of medicinal substances, study of relative heat stabilities 
and dynamic properties of new compounds, as well as in crystallography, 
chemical kinetics and generation of phase diagrams5. Most thermodynamic 
events are accompanied by a loss of heat or require addition of heat from an 
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( external source in order to proceed. Each of these occurrences can be followed 
thermodynamically by noting either change of temperature of the sample under 
study or energy changes of the sample with respect to time. Thermal analyses 
include thermogravimetry (thermogravimetric analysis, TGA), differential 
thermal analysis (DT A) and differential scanning calorimetry (DSC). DSC is 
very closely related to TGA, but differs only in that the sample and reference 
containers are not contiguous, but are heated separately by individual coils that 
are heated (or cooled) at the same rate. Platinum resistance thermometers monitor 
the temperature of the sample and reference holders and electronically maintain 
the temperature of the two holders constant. If a thermodynamic event occurs 
which is either endothermic or exothermic, the power requirements for the coils 
maintaining a constant temperature will differ. This power difference is plotted as 
a function of the temperature recorded by the programming device. Unlike DT A, 
in DSC the amount of heat put into the system is exactly equivalent to the amount 
of heat absorbed or liberated during a specifc transition (transition energy). 
1.4.3 Optical Microscopy 
The past decade has witnessed an enormous growth in the application of optical 
microscopy for micron and sub-micron level investigations in a wide variety of 
disciplines. Microscopy 
has been used quite often to study the morphology of solids, alone, in mixtures or 
dispersions, and in polymorphism. The properties of the particles in a powder can 
influence profoundly the pharmaceutical performance of the solid, such as the 
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processmg, compaction, stability, and/or release rate of the active constituent. 
Optical microscopy can be used to study the crystal habit (shape and roughness) 
of crystalline substances. 
The physical characterization of amorphous solids utilizes a wide range of 
techniques and offers several types of information 12 : 
1. Structure. Amorphous solids are not random at the molecular level, but 
may possess short-range order, residual crystallinity, polymorphic states 
and regions of different density. 
2. Thermodynamics. Amorphous solids have higher energy, entropy and 
free energy than the corresponding crystals. The excess properties are 
parameters in some theoretical models of crystallization and structural 
relaxation. 
3. Changes. Amorphous solids can crystallize or undergo structural 
relaxation owing to the instability with respect to the corresponding 
crystals and "equilibrium" glasses. 
4. Multi-component systems. Many pharmaceutical formulations are multi-
component, with water being a ubiquitous ingredient. It is desirable to 
predict properties of multi-component systems from those of individual 
components. 
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1.5 Cefuroxime Axetil 
Cefuroxime axetil (CA), an acetoxyethyl ester prodrug of cefuroxime, was the 
first oral cephalosporin of the second generation to be commercially available as 
tablets in 198967 . Cefuroxime has a broad spectrum of in vitro antibacterial 
activity which encompasses methicillin-sensitive staphylococci and the common 
respiratory pathogens Streptococcus pneumoniae, Haemophilus influeza, 
Moraxel/a (Branhamella) catarrhalis and group A P-heamolytic streptococci68 . It 
has broad spectrum activity against the P-lactamase positive respiratory pathigens 
H. injluenzae and M catarrhalis; it shows activity against penicillin-susceptible 
and - intermediate strains of S. pneumoniae. Cefuroxime axetil is indicated for the 
treatment of patients with mild to moderate infections caused by susceptible 
strains of the designated microorganisms in the following conditions - pharyngitis 
I tonsillitis (caused by Streptococcus pyogenes), acute baterial otitis media 
(caused by S. pneumoniae, H. influenzae, M catarrhalis or S. pyogenes ), acute 
bacterial maxillary sinusitis (caused by S. pneumoniae or H. injluenzae) , acute 
bacterial exacerbations of chronic bronchitis and secondary bacterial infections of 
acute bronchitis (caused by S. pneumoniae, H. influenzae, or H. parainjluenzae), 
uncomplicated skin and skin structure infections (caused by Staphylococcus 
aureus or S. pyogenes ), uncomplicated urinary tract infections (caused by 
Escherichia coli or Klebsiella pneumoniae), uncomplicated gonorrhea (caused by 
Neisseria gonorrhoeae), and early Lyme disease (caused by Borrelia 
burgdorferi). Since cefuroxime is not absorbed orally, its use for outpatient 
treatment of community acquired infections is limited. Cefuroxime axetil, the 
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( orally absorbed prodrug, is formed by esterification of the parent cefuroxime 
molecule. The 1-(acetyloxy) ethyl ester group enhances lipid solubility and 
gastric stability and facilitates oral absorption69 . It exists as a 50:50 mixture of 
diastereomers A and B. After oral administration, CA is absorbed from the GIT 
and rapidly hydrolyzed (within 3-4 minutes) by non-specific esterases in the 
intestinal mucosa and blood to yield the active parent compound, cefuroxime (see 
Figure 4), which is subsequently distributed throughout the extracellular fluids. 
The in vivo bactericidal activity of cefuroxime axetil is due to cefuroxime's 
binding to essential target proteins and the resultant inhibition of cell-wall 
synthesis70 . Peak plasma cefuroxime concentrations of approximately 4.1 to 4.8 
mg/L are attained 2 to 2.5 hours after a single oral dose of cefuroxime axetil 250 
mg (tablet formulation). The absorption of cefuroxime axetil is significantly 
increased by the presence of food. In one study, the bioavailability of cefuroxime 
increased from 36% in fasted individuals to 52% when the drug was administered 
with food. The volume of distribution of cefuroxime is 0.25 to 0.3 L/kg and the 
drug is approximately 33% plasma protein bound. Distribution of cefuroxime 
into body tissues and fluids is variable, but the drug penetrates well (35 to 90%) 
into tonsil tissue, sinus tissue and bronchial mucosa; mean tissue concentrations 
of cefuroxime ranged from 1.4 to 3 .8 mg/kg. After administration of single doses 
of cefuroxime axetil (250 to 1 OOOmg), the plasma elimination half-life of the drug 
ranged from 1.1 to 1.5 hours in healthy volunteers with normal renal function, but 
was significantly increased by moderate to severe renal impairment. Cefuroxime 
is not significantly metabolized and is eliminated by the kidneys as unchanged 
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( drug, resulting in high urinary concentrations of cefuroxime. Cefuroxime axetil is 
associated with a low incidence of adverse events, with gastrointestinal 
disturbances being the most frequently observed. Thus it is an effective and 
convenient treatment for a wide range of infections, and may be considered a 
therapeutic option when empirical treatment of community-acquired infections is 
required. 
1.6 Objectives of the Study 
The crystalline nature of a drug has a direct effect on its solubility, and may be a 
limiting factor for its dissolution and bioavailability. A reduction in the 
crystallinity of the drug or its conversion to the zero - crystalline (amorphous) 
state, would be a means of enhancing the bioavailability of the drug. However, 
the unstable nature of the amorphous state, accelerated by external factors (e.g. 
moisture), limits its wider and more frequent application. 
This study primarily investigates the effect of crystal modification on the 
solubility of CA and its individual isomers. Techniques used have been employed 
with the aim of altering the crystal structure. A comparative study between the 
processes has also been used to determine the varied effect on the solid-state of 
the drug. Polymers have also been used, in conjunction with the processes; to 
investigate any positive effect on the ability of the drug to retain its modified state 
(of improved solubility). Use of polymers has been considered as they not only 
assist in improving solubility; but can also act as impurity (in small quantities), to 
destabilize the rigid crystal structure. Since the drug exists as a mixture of 
29 
( diastereoisomers, we can expect a difference in the effects of the processes and 
polymers on the individual isomers. Diastereoisomers have different solubilities 
and melting points, and hence will show differences in the degree of conversion 
from crystalline to partially crystalline to amorphous states. 
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SECTION II: EXPERIMENTAL 
41 
The solid state of a drug affects its solubility, and in tum its dissolution and 
bioavailability from the dosage form. The existence of the drug in the 
crystalline or amorphous form needs to be adequately characterized. Crystalline 
to partially crystalline or amorphous conversions have been studied in this 
project. The primary aim of this study was to determine the effect of processes 
and polymers on the crystalline to amorphous conversions and their effect on the 
aqueous solubility of the drug. Solubility is one of the parameters used to 
monitor these conversions. In addition, analytical techniques like DSC 
(Differential Scanning Calorimetry), XRD (X-Ray Diffraction), and optical 
microscopy were used to characterize these conversions. 
2.1 Assay for Cefuroxime Axetil (CA) 
2.1.1 Equipments I Reagents: 
Equipments 
Mettler AE 240 Weighing balance 
Ultrasonifier (Fisher Scientific) 
HPLC System consisting of: 
Automated Gradient Controller (Waters®) 
HPLC Pumps (Waters® Model 515) 
Auto Sampler (Waters® Model 717 plus) 
LC Spectrophotometer (Waters® Model 480) 
Data Module (Waters® Model 746) 
L-13 column (YMC®) 
Column Temperature Controller (Fiatron Systems Inc, Model TC-50) 
42 
Reagents 
Cefuroxime Axetil (Hanmi Pharmaceuticals, Batch# CF A - L99003) 
Cefuroxime Axetil (USP Reference Standard) 
Ammonium Phosphate Monobasic (HPLC Grade, Fisher Scientific) 
Methanol (HPLC Grade, Fisher Scientific) 
Deionized water. 
2. I. 2 Standard Procedure: 
1) Mobile phase used m this study is a mixture of 0.2 M monobasic 
ammonium phosphate and methanol (620:380). 
2) Stock solution (1 mg/ml) of cefuroxime axetil in methanol is used for the 
preparation of the standard solutions. 
3) Standards are made by serial dilutions of the stock solution with the 
mobile phase, to give concentrations of 10 µg/ml, 20 µg/ml, 40 µg/ml, 
60 µg/ml, 80 µg/ml, 100 µg/ml and 200 µg/ml. 
4) The HPLC system was prepared by setting the following parameters, 
a) The column thermostat temperature should be set to 32 °C. 
b) The absorbance of the spectrophotometer should be set to 278 
nm. 
c) The flow rate should be set to 1 ml/minute. 
d) The run time should be set to 15 minutes. 
e) Injection volume should be set to 10 µ1. 
f) Number of injections from each vial should be set to 2. 
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( 5) The assay for the USP reference standard and the sample of cefuroxime 
axetil were identical, performed using the standard procedure above. 
6) The calibration curve is constructed by plotting the area under the curve 
(AUC) against their concentrations. 
7) Since the drug exists as a mixture of diastereoisomers, the total 
concentration 1s given by the sum total of the concentration of the 
individual isomers. 
8) Separate calibration curves for the individual isomers as well as the total 
drug have been constructed, which can be used to determine the 
unknown concentration of the samples. 
9) Validation of the assay for cefuroxime axetil was performed over five 
days to ensure reproducibility. 
The drug exists as a mixture of diastereoisomers A and B that elute separately. 
Isomer B (-10.5 min) elutes first followed by isomer A (-11.5 min) with a 
difference of approximately 1 minute between them (see Figure 5). 
Table 3 shows the data for the calibration curve of the USP reference standard. 
From the tables we see that the ratio of the isomers, B (0.48) to A (0.52), lie 
within the USP limits of 0.48 to 0.55 . Figures 6 and 7 illustrate the complete as 
well as linear portion of the calibration curve of the USP reference standard and 
its individual isomers, respectively. 
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10.5 min 
11.6 min 
Isomer B 
Isomer A 
Figure 5: Chromatogram showing the peaks of isomers Band A, eluting 
at 10.5 min and 11.6 min 
45 
+:>. 
0\ 
Concentration AUC AUC Total AUC 
(ug/ml) Isomer B Isomer A 
0 0 0 0 
10.08 139424 149775 289199 
20.16 302160 323067 625227 
40.32 625688 669151 1294839 
60.48 950409 1007543 1957952 
80.64 1328578 1411506 2740084 
100.8 1609064 1697853 3306917 
201.6 3182848 3368529 6551377 
Table 3: Data for calibration curve of cefuroxime axetil 
........._ 
Cone. (Isomer B) Cone. (Isomer A) Isomer B Isomer A 
(µg/ml) (µg/ml) (%) (%) 
0 0 0 0 
4.86 5.22 48.21 51.79 
9.75 10.42 48.33 51.67 
19.48 20.84 48.32 51.68 
29.36 31.12 48.54 51.46 
39.09 41.54 48.49 51.51 
49.05 51.75 48.66 51.34 
97.94 103.66 48.58 51.42 
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Figure 6: Representative calibration curve for cefuroxime axetil 
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( Table 4 shows the data for the calibration curve of cefuroxime axetil. Tables 5 
and 6 show the data in terms of the individual isomers A and B. Table 7 shows 
the percentage of isomers A and B in the cefuroxime axetil sample, and it can be 
seen that the ratio of the isomers lie within the USP limits. Figures 8 and 9 
illustrate the linear portion of the calibration curve for the sample and its 
individual isomers, respectively. The correlation coefficient was found to be 
0.9995 and 1.0 for cefuroxime axetil (USP) and the cefuroxime axetil sample 
respectively. 
Table 8 shows the mean values of the data generated out of five days of 
replication studies for seven separate and distinct samples for series of 
cefuroxime axetil concentrations ranging from 10 to 200 µg/ml. 
The purity of the sample of cefuroxime axetil was determined as shown in Table 
9. The average percentage purity was found to be 103.85% with a standard 
deviation of 4.462, when compared to the USP reference standard. 
2.2 Solubility Studies of Cefuroxime Axetil 
Solubility studies of the drug were carried out in water and 0.07 N HCl, for a 
period of 24 hours with samples withdrawn and analyzed at seven time intervals. 
The 24-hour time duration was selected to allow the drug to reach its 
equilibrium solubility. The USP dissolution test for cefuroxime axetil tablets 
uses 0.07 N HCl as the dissolution medium in order to simulate gastric 
conditions; hence it has been selected as one of the media for solubility studies. 
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0 
Concentration Av. AUC Av. AUC Av. AUC Av. AUC 
(µg/ml) [1] [2] [3] [4] 
10 312426 314608 332367 319419 
20 643677 637731 631992 685701 
40 1286830 1277833 1297919 1392295 
60 1918719 1911772 1938960 2171403 
80 2594779 2545924 2556001 2803400 
100 3229755 3197528 3188288 3485069 
200 6464686 6347863 6411309 7092098 
Table 4: Data for calibration curve of total concentration of cefuroxirne axetil 
' 
Av. AUC Av. AUC Std. Dev. 
[5] 
331576 322079 8391.76 
675389 654898 21512.76 
1391674 1329310 51567.87 
2167442 2021659 120984.89 
2792579 2658536 115076.64 
3491175 3318363 139303.25 
7013097 6665810 318948.92 
Vl 
,_. 
Concentration Av. AUC Av. AUC Av. AUC 
(µg/ml) [1] [2] [3] 
10 160575 162050 170916 
20 331119 327530 323917 
40 660897 652037 664676 
60 982291 975823 992157 
80 1328460 1297967 1306663 
100 1656111 1645014 1635584 
200 3328511 3258313 3294722 
Table 5: Data for calibration curve of isomer A of the drug 
---..., 
Av. AUC Av. AUC Av. AUC Std . Dev. 
[4] [5] 
163362 168946 165170 4034.41 
351588 345187 335868 10666.32 
712155 711938 680340 26210.80 
1113526 1114671 1035693 64229.22 
1431649 1433550 1359657 60382.51 
1786412 1794267 1703477 71262.75 
3651349 3601925 3426964 165277.89 
VI 
N 
/'-
Concentration Av. AUC Av. AUC Av. AUC 
(µg/ml) [1] [2] [3] 
10 151850 152557 161451 
20 312558 310201 308075 
40 625933 625795 633243 
60 936428 935949 946803 
80 1266319 1247956 1249338 
100 1573644 1552513 1552704 
200 3136174 3089549 3116586 
Table 6: Data for calibration curve of isomer B of the drug 
,.-- ) 
Av. AUC Av. AUC Av. AUC Std . Dev. 
[4] [5] 
156056 162630 156909 4440.95 
334113 330202 319030 10882.69 
680140 679736 648969 25429.3 
1057877 1052771 985965 56786.6 
1371751 1359029 1298879 54837.97 
1698657 1696908 1614885 68122.07 
3440749 3411172 3238846 153778.6 
VI 
w 
' 
Concentration Av. AUC Av. AUC Av. AUC Concentration Concentration % isomer A % isomer B 
(µg/ml) (total) (isomer A) (isomer B) (isomer A) (isomer B) 
(µg/ml) (µg/ml) 
10 322079 165170 156909 5.13 4.87 51.28 48.72 
20 654898 335868 319030 10.26 9.74 51.29 48.71 
40 1329310 680340 648969 20.47 19.53 51.18 48.82 
60 2021659 1035694 985965 30.74 29.26 51.23 48.77 
80 2658536 1359658 1298879 40.92 39.09 51.14 48.86 
100 3318363 1703478 1614885 51.33 48.67 51.34 48.67 
200 6665810 3426964 3238846. 102.82 97.18 51.411 48.59 
Table 7: Percentage of isomers A and B determined from the calibration data of total drug and the individual isomers 
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Figure 8: Representative calibration curve from the replication study for cefuroxime axetil 
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Figure 9: Representative calibration curve for isomers A and B from the replication study for cefuroxime axetil 
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Vi 
0\ 
-, 
Isomer A Isomer B Total 
Concentration 
(ug/ml) Av. AUC Std. Dev. %CV Av. AUC Std. Dev. %CV Av. AUC Std. Dev. 
10 165170 4034.41 2.44 156909 4440.95 2.83 322079 8391.75 
20 335868 10666.32 3.17 319030 10882.69 3.41 654898 21512.75 
40 680341 26210.8 3.85 648970 25429.3 3.92 1329310 51567.86 
60 1035694 64229.22 6.2 985966 56786.59 5.76 2021660 120984.89 
80 1359658 60382.51 4.44 1298879 54837.97 4.22 2658537 115076.63 
100 1703478 71262.75 4.18 1614886 68122.07 4.21 3318363 139303.25 
200 3426964 165277.89 4.82 3238846 153778.63 4.75 6665811 318948.91 
Table 8: Reproducibility of cefuroxime axetil from standard solutions over 5 days ofreplication studies 
----.. 
%CV 
2.61 
3.28 
3.87 
5.98 
4.32 
4.19 
4.78 
Vi 
-...) 
,..., 
-----.. 
Cefuroxime Axetil (USP Std .) Cefuroxime Axetil (sample) 
Theoretical Experimental % Purity 
Concentration Total AUG Concentration Total AUG Concentration 
(µg/ml) (µg/ml) (µg/ml) 
10.08 289199 10 322079.2 11.23 112.26 
20.16 625227 20 654898.3 21.12 105.58 
40.32 1294839 40 1329310.4 41.39 103.48 
60.48 1957952 60 2021659.6 62.45 104.08 
80.64 2740084 80 2658536.9 78.24 97.80 
100.8 3306917 100 3318363.4 101.15 101.15 
201.6 6551377 200 6665810.7 205.12 102.56 
Average 103.85 
Std . Dev. 4.46 
Table 9: Determination of the percentage purity of the cefuroxime axetil sample based on the USP reference standard 
As observed from the solubility profile of the drug (Figure 10), CA reaches its 
equilibrium solubility by 4 hours and remains at equilibrium for over 10 hours. 
An excess amount of the drug in the medium ensured equilibrium and also 
accounted for any degradation that may have taken place during the 24 hour 
time period. The studies were conducted at room temperature (25 °C). Previous 
studies have shown that CA undergoes hydrolytic degradation in solution 1• The 
first-order hydrolysis kinetics of CA was investigated as a function of pH, 
temperature, buffers, and ionic strength. Chromatographically identified 
hydrolysis products were cefuroxime, ~2-cefuroxime axetil, and a, ~-sulfoxides. 
Experimental Design: For these studies, excess amount of the sample (~30-40 
mg) was weighed and transferred to a glass vial. After addition of 4 ml of the 
medium, the vials were allowed to equilibrate on a rotary mixer for 24 hours. 
Samples were withdrawn at intervals of 10 min, 30 min, 45 min, 1 hr, 2 hr, 4 hr, 
8 hr and 24 hr. The solution was filtered, diluted with mobile phase and 
analyzed by HPLC. The solubility determination of each sample was done in 
triplicate. The concentration of the drug in solution was determined using the 
standard curves. 
The solubility of the USP reference standard was determined in water and 0.07 
N HCl (see Figure 11). The untreated cefuroxime axetil sample was first tested 
to determine its solubility profile. The drug was then treated with a combination 
of processes and polymers. The solubility of these processed mixtures was then 
determined by the above procedure. The purity of the drug after treatment (with 
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Figure 10: Solubility profile of untreated cefuroxime axetil in water and 0.07 N HCl (average of n = 3, ±S.D.) 
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Figure 11: Solubility profile of cefuroxime axetil in water and 0.07 N HCl (average of n = 3, ±S.D.) 
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( process and/or polymer), was also determined to rule out any interactions /loss 
/degradation of the drug. 
2.3 Modification of Physical State 
This section deals with the various processes and polymers that were employed 
to bring about a modification in the solid state of the drug. Each factor is dealt 
with individually in a separate sub-section. 
2.3.1 Selection of Polymers 
The use of a polymer serves three purposes; enhances solubility, acts as an 
impurity to destabilize the rigid crystal structure2• 3• 4, and in the amorphous 
state, assists in preventing the re-conversion of the unstable amorphous state to 
its stable crystalline state5. This approach was adopted as the unstable nature of 
the amorphous state was recognized and known to limit its wider application. 
Amorphous substances cannot achieve their maximum theoretical solubility 
under practical experimental conditions because of the strong driving force for 
crystallization in the presence of the dissolution media6. Several previous 
workers have tried to avoid this problem by adding crystallization inhibitors to 
their dissolution media7• 
The polymers selected were Eudragit EPO, Eudragit RD 100 and 
Polyvinylpyrrolidine (PVP Cl 5). 
61 
( Eudragit @ EPO supplied by Rohm America, in the powder form and 1s a 
cationic polymer with a dimethyl-aminoethyl ammonium functional group. It is 
a pH dependent polymer and is soluble in gastric fluid up to pH 5.0, and 
swellable and permeable above pH 5.0. It has taste masking and odor masking 
properties8. 
Eudragit @ RD JOO supplied by Rohm America, as powder and is based on 
Eudragit RL 100 (copolymer of acrylate and methacrylates with quaternary 
ammonium group as a functional group) and Na-CMC. It forms rapidly 
disintegrating films that are independent of pH8. 
Both the Eudragits are used for immediate release coatings. 
PVP Cl 5 provided by ISP Technologies Inc., in the powder form and is a 
synthetic water-soluble polymer. It has a K-value of 16-18, a molecular weight 
of 8,000 and a typical viscosity of 1.5 rnPa.s. The K-value is calculated from 
the kinematic viscosity of a 1 % aqueous solution and hence is related to the 
average molecular weight of the polymer. It is also soluble in a wide range of 
organic solvents enabling its use in water sensitive pharmaceutical dosage 
forms . The viscosity of PVP in aqueous solution is unaffected by pH and salt 
concentration9. 
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( 2.3.2 Selection of Processes 
In this study, the process of microfluidization has been used to assist m 
converting the drug from its crystalline to amorphous form. Microfluidization is 
a widely used technique for the homogenization of emulsions and dispersions, 
liposomes and cell disruption. The M-11 OS Microfluidizer® Processor 
(Microfluidics Corporation, Newton, MA) shown in Figure 12, contains an air-
powered intensifier pump designed to supply the desired pressure at a constant 
level to the product stream 10• As the pump travels through its pressure stroke, it 
drives the product at a constant pressure through precisely defined fixed-
geometry microchannels within the interaction chamber (Figure 13). As a 
result, the product stream accelerates to high velocities, creating shear rates 
within the product streams that are orders of magnitude greater than any other 
conventional means. All of the product experiences identical processing 
conditions, producing the desired results, including uniform particle size, and 
droplet size reduction (often submicron), deagglomeration, and high yield cell 
disruption. This study uses an existing technique for a new application, the 
modification of the crystal structure. A solution of the drug and/or polymer in 
an appropriate solvent system was prepared, and then passed through the 
microfluidizer under a defined set of conditions. The solvents were removed, 
and the treated drug characterized by solubility, DSC, XRD and microscopy. A 
system of drug/polymer in similar solvents was also prepared by solvent 
evaporation to study effects of solvent, if any. A physical mixture of the drug 
and polymer was also studied to determine any effects of polymer in the absence 
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Figure 12: Picture of the M-1 lOS Microfluidizer processor, Microfluidics 
Corp. 
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Figure 13 : Diagram showing the parts and dimensions of the M-1 lOS Microfluidizer, Microfluidics Corp. 
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( of the processes. The ratio of polymer in the drug-polymer mixture has been 
kept at a minimum. Throughout the studies the ratio of drug:polymer has been 
kept constant at 9: 1. Low amounts of polymer can act as impurities in the 
destabilization of the crystal structure. 
Experimental Design I: The drug and/or polymer were weighed out (900 mg 
drug + 100 mg polymer) and dissolved by sonication in 20 ml of a 1: 1 :2 mixture 
of acetone, methanol and ethanol. The pressure gauge of the micro fluidizer was 
set at 40 psi. The solution was then passed through the equipment for 10 strokes 
of the pump and collected from the outlet. The solution was decolorized with 
charcoal to adsorb any impurities and to ensure a product with an acceptable 
color (white to pale yellow), and filtered under vacuum. The filtered solution 
was transferred to a glass evaporating dish that was placed under the vacuum 
hood, and the solvents were allowed to evaporate at room temperature. After 
the complete evaporation of the solvents, the sample was dried under vacuum in 
a dessicator for 24 hours or until no further loss in weight was observed. The 
sample was collected, percent yield determined and then stored in glass vials in 
a dessicator placed in a refrigerator, for further use. 
Experimental Design II: The drug and/or polymer were weighed out (900 mg 
drug + 100 mg polymer) and dissolved by sonication in 10 ml of a 1: 1 mixture 
of acetone and methanol. The solution was decolorized with charcoal, filtered 
under vacuum and then transferred to an evaporating dish. The solvents were 
allowed to evaporate at room temperature under the vacuum hood, and then the 
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( samples were transferred to a dessicator in which they were further dried for 24 
hours or until no further loss in weight occurred. The samples obtained were 
weighed to determine the percent yield and were henceforth stored under 
vacuum in a refrigerator. 
Experimental Design III: The drug and/or polymer were weighed out (900 mg 
drug + 100 mg polymer) and transferred to a glass vial. The vial was placed on 
the rotary mixer for 10 min to ensure proper mixing of the drug and the polymer. 
This physical mixture of the drug and polymer was then used for solubility 
determinations and other characterizations. 
Table 10 lists all the drug-polymer-process combinations that have been studied 
in this project. 
2.3.3 DSC Studies 
DSC analysis was carried out usmg Perkin Elmer DSC7 (Perkin Elmer, 
Wellesley, MA). Samples were weighed (approximately 10 mg), sealed in 
aluminum pans and loaded into the pan holder. An empty pan was used as 
blank. The scanning rate was set to 10 °C/min. Three separate samples were 
tested for the drug and each of the processed mixtures. 
2.4 Results and Discussion 
The solubility profiles of the USP reference standard (Figure 11) and the sample 
(Figure 10) were determined. The USP reference standard was found to be in 
the amorphous form, as confirmed by the XRD data which showed an absence 
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00 
No. Drug Polymer Process 
1 CA - -
2 CA - Microfluidization 
3 CA - Solvent Evaporation 
4 CA PVP -
5 CA Eud EPO -
6 CA Eud RD 100 -
7 CA PVP Microfluidization 
8 CA Eud EPO M icrofl u id izatio n 
9 CA Eud RD 100 M icrofl u id izatio n 
10 CA PVP Solvent Evaporation 
11 CA Eud EPO Solvent Evaporation 
12 CA Eud RD 100 Solvent Evaporation 
Table 10: The combinations of drug-polymer-process that have been studied 
." 
of peaks (see Figure 14). Over the duration of the solubility experiments, the 
amorphous starting material begins converting to its stable crystalline form, as 
evident from the solubility profile of the USP reference standard (Figure 11 ). 
The commercial sample exhibited multiple peaks in the XRD (Figure 15) 
indicating the presence of the crystalline form. The DSC data for the 
commercial sample (Figure 16) shows the presence of two melting endotherms, 
at 123 °C and at 173 °C, for the two isomers B and A, respectively. The drug 
degrades (at - 175 °C) after the melting of the second isomer, as observed from 
the loss of the straight nature of the baseline. Also, visual examination shows 
browning and charring of the drug after - 176 °C when examined on the melting 
point apparatus. The drug in the solid form exists as a 1: 1 mixture of the two 
isomers, A and B. However, in solution, isomer B is in greater concentration 
than isomer A due to its significantly greater solubility. In aqueous solution, the 
ratio of the solubilized isomers is 9: 1 (B:A) (see Figure 17). This is also true for 
the solubility determinations made in 0.07 N HCl. The solubility of isomer B is 
-5 times the solubility of isomer A (Figure 18). 
Solubility determinations, using excess amounts of drug, follow a zero-order 
kinetics, in which the concentration in solution depends on the drug's solubility. 
Excess drug replaces any drug lost due to degradation in solution, whereby more 
drug is released from the suspended particles so that the amount of dissolved 
drug remains constant. This concentration is the drug's equilibrium solubility in 
a particular solvent at a particular temperature 11 • It is important to note that the 
amount of drug in solution remains constant despite its decomposition with time. 
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Figure 14: XRD scan of the USP reference standard of cefuroxime axelil 
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Figure 18: The solubility profile of isomers A and B in water and 0.07 N HCl 
( Degradation of CA was observed from the appearance of multiple peaks on the 
chromatograms in addition to the isomer peaks. The initial rate of solubilization 
of the drug varies hyperbolically with time. During the initial time period, the 
drug goes into solution continuously, increasing the concentration of the drug 
linearly. This approximates first-order kinetics in that the rate of dissolution is 
proportional to time. As the time increases, more and more drug goes into 
solution, until the solution is saturated with the drug, and zero-order or 
saturation kinetics is observed. 
In the following section, the effect on solubility of the drug has been compared 
in the absence and in the presence of the selected polymers. 
2.4. I Effect of crystalline to amorphous conversion on solubility of the drug in 
the absence of polymers 
The solubility profiles of the untreated drug, its microfluidized form and its 
recrystallized form were examined. As seen in Figure 19 both the processes 
bring about an increase in the solubility of CA. However, the recrystallized 
drug shows a dramatic decrease in solubility after the first two hours, reducing 
the amount of drug dissolved to the solubility of untreated CA after 24 hours. 
This indicates conversion of the amorphous (high solubility) form to its 
crystalline (low solubility) form. Similar observations of amorphous to 
crystalline conversion during solubility studies have been made for drugs like 
indomethacin and griseofulvin6. The microfluidized drug shows a very gradual 
decrease in solubility and would eventually reach the equilibrium solubility of 
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Figure 19: Solubility profile of untreated, microfluidized and recrystallized cefuroxime axetil in 0.07 N HCl (average of n = 3, 
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""' 
I untreated CA. However, the solubility after 24 hours is still twice the solubility 
of the untreated and recrystallized CA. 
Further examination of the solubility profile, in terms of the individual isomers 
of the drug, provides a better understanding of the effect of the treatment 
processes. The untreated solid drug is a 1: 1 mixture of the two isomers, 
however, in solution, the composition of the mixture is 1 :9 (A:B). The 
microfluidized sample, on the other hand, shows a change in this composition 
from 1 :9 to 2:3, and more or less maintains that composition for the entire 24 
hours over which the sample was tested (see Figure 20). As for the 
recrystallized sample, the composition changes gradually over the period of 
time. During the initial 2 hours the composition of the isomers in solution is 3:7 
(A:B) which changes to 2:3 at the end of the 24 hours; while the total solubility 
of the drug falls from -3 times the original, at 2 hours, to the original, at the end 
of the 24 hours. Thermal analysis of CA shows the presence of two melting 
endotherms. Isomer B melts at 123 °C while isomer A melts at a higher 
temperature of 173 °C (Figure 16). The lower melting isomer shows a greater 
solubility. The DSC scans for the recrystallized mixture show the presence of 
the melting endotherm at 173 °C which indicates the presence of isomer A, 
while the endotherm for isomer B is not present. However, the heat of fusion of 
the recrystallized isomer A is lower than that of the pure isomer A (Table 11 ). 
Thus isomer A retains its crystalline form, albeit with defects to the crystal 
structure, indicated by a lower heat of fusion. The rnicrofluidized CA shows an 
absence of both the endotherms. Thus, the microfluidized CA is in the 
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\0 
Isomer A Heat of Fusion 
(J/g) 
CA (untreated) 18.93 
CA (recrystallized) 11.55 
CA + PVP (recrystallized) 8.67 
CA+ Eudragit RD100 (recrystallized) 10.78 
Table 11: Heat of fusion (J/g) of isomer A for the different process-polymer combinations (the remaining process-polymer 
combinations convert the isomers to its amorphous form) 
~ 
( amorphous form while the recrystallized drug is in a partially crystalline state. 
This is also confirmed by the comparison of the XRD data shown in Figure 21. 
The solubility and DSC data indicate that the higher solubility, lower melting 
isomer (B) is affected by both the processes and is converted to its amorphous 
form. In the case of the recrystallized sample, isomer (B) loses its amorphous 
form on prolonged exposure to the medium, as indicated by the downward slope 
of the solubility curve (Figure 19). However, the microfluidized drug shows 
only a gradual decrease in the solubility indicating a greater resistance to 
conversion to its original form. The use of microfluidization for these 
conversions has not been studied previously and is a new phenomenon. The 
drug is subjected to high pressure and velocities causing complete disruption of 
the crystal structure. Pharmaceutical solids, as we know them, rarely exist as 
100% crystalline or 100% amorphous phases 12• The presence of domains of one 
phase in another can act as a focal point for spontaneous phase transitions such 
as crystallization13' 14' 15. The process of microfluidization is likely to have 
reduced drastically the number of such domains, thereby decreasing initiation 
sites for crystallization and preventing rapid reconversion to the crystalline 
form. Microscopic analysis shows CA to be in a crystalline state with needle 
shaped crystals. The microfluidized and recrystallized samples show a loss of 
the needle shaped structure to give a more irregular appearance (Figures 22 and 
23). 
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Figure 22: Optical microscopic image of cefuroxime axetil showing needle shaped crystals 
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Figure 23: Optical microscopic image of treated cefuroxime axetil showing loss of needle shaped crystals 
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( 2.4.2 Effect of crystalline to amorphous conversion on solubility of the drug in 
the presence of polymers 
The crystalline to amorphous conversion of the drug was also examined in the 
presence of several selected polymers. The physical mixtures of the drug and 
the three polymers were tested to rule out any positive effect on the solubility of 
the drug in the absence of the processes. The following section compares only 
the nine mixtures that involve the three polymers (Table 10 - Nos. 4-12). 
Figures 24 and 25 show the solubility profile of the drug and its physical 
mixtures with PVP, Eudragit EPO and Eudragit RDlOO, determined in 0.07 N 
HCl and water, respectively. A look at the solubility profiles shows a 10-50 
µg/ml increase in solubility for all the physical mixtures at any given time point. 
The physical mixtures of all the three polymers show no significant increase in 
solubility and hence can be considered equivalent to the untreated drug for all 
practical purposes. The XRD (Figure 26) data does not show the presence of 
any additional peaks and is comparable to the XRD pattern of the untreated 
drug. The DSC data of the physical mixtures also does not show any changes in 
the melting endotherms of the isomers, from that of the untreated drug. Table 
12 shows the purity of the physical mixtures that were found to be very close to 
or equal to (between 99-101 %) the pure drug. Thus, we can safely conclude that 
there is no form of chemical interaction between the drug and any of the three 
polymers in their physical mixtures. When the drug and polymer combinations 
are subjected to the process of microfluidization and recrystallization, solubility 
profiles are as shown in Figures 27 and 28. It is evident that PVP when 
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Figure 24: Solubility profile of cefuroxime axetil and its physical mixtures with PVP, Eudragit EPO and Eudragit RD 100, 
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Figure 25: Solubility profile of cefuroxime axetil and its physical mixtures with PVP, Eudragit EPO and Eudragit RD 100, 
in water 
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Cefuroxime Axetil Physical Mixtures of CA and Polymers 
Total AUG Experimental Total AUG Theoretical % Purity !Average 
Concentration Concentration Concentration 
(µg/ml) (µg/ml) (µg/ml) 
CA+ PVP 
20 654898 20 649876 19.85 99.23 
60 2021660 60 2034544 60.38 100.6 99.74 
100 3318363 100 3296875 99.35 99.35 
CA+ Eudra_g_it RD 100 
20 651984 19.91 99.55 
60 2010431 59.67 99.44 99.54 
100 3305816 99.62 99.62 
CA+ Eudra_g_it EPO 
20 660124 20.16 100.8 
60 2031254 60.29 100.5 100.54 
100 3330125 100.35 100.4 
Table 12: Purity data of physical mixtures of cefuroxime axetil with polymers - PVP, Eudragit RDlOO and Eudragit EPO 
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Figure 27: Solubility profile of untreated and microfluidized cefuroxime axetil - with PVP, Eudragit EPO and 
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( subjected to the two aforementioned processes shows a greater increase in 
solubility as compared to that caused by the other two polymers. There is an 
approximate 3-fold increase in solubility with the use of PVP, and only a 2-fold 
increase with the use of the Eudragits. Both the Eudragits show an increase in 
solubility to approximately the same extent, with Eudragit RDlOO showing a 
slightly greater increase. The purity of these samples was determined and the 
data has been tabulated in Table 13. The purity of drug in the presence of 
Eudragit EPO, after treatment with either of the processes, was found to be very 
low (76.3% and 80.6% for the microfluidized and recrystallized drug 
respectively). The low purity of the drug can be attributed to the formation of a 
complex between the cationic polymer and the anionic drug. This complex is 
detected on the chromatogram (shown in Figure 29) as a third peak eluting at 
12.5 min after those of the two isomers A and B. When the solubilities of the 
microfluidized and recrystallized samples of drug are compared with respect to 
the individual polymers (Figures 30, 31, 32), it was noticed that there is not 
much difference between the microfluidized and recrystallized samples. The 
differences in solubility range from 20-100 µg/ml with the greatest difference 
seen for the samples using Eudragit EPO. The microfluidized and recrystallized 
samples show an almost equivalent increase in solubility as seen in Figures 30, 
31, 32. 
The X-ray diffraction data for the recrystallized - PVP, Eudragit EPO, and 
Eudragit RDlOO samples are shown in Figure 33. The sample containing 
Eudragit EPO is totally amorphous, while those containing PVP and Eudragit 
91 
l.O 
N 
............ 
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Cefuroxime Axetil Microfluidized Samples of CA and Polymers Recrystallized Samples of CA and Polymers 
Total Experimental Total Theoretical Purity Average Experimental Total Theoretical Purity Average 
Cone. AUC Cone. AUC Cone. (%) Cone. AUC Cone. (%) 
(µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) 
CA+ PVP CA+ PVP 
20 654898 20 645149 19.70 98.51 20 652168 19.92 99.58 
60 2021660 60 1945851 57.75 96.25 96.93 60 2014763 59.79 99.66 99.55 
100 3318363 100 3186489 96.03 96.03 100 3298689 99.41 99.41 
CA + Eudra_g_it RD 100 CA + Eudra_g_it RD 100 
20 635965 19.42 97.11 20 642781 19.63 98.15 
60 1915728 56.86 94.76 95.08 60 1986573 58.96 98.26 97.77 
100 3098787 93.38 93.38 100 3214893 96.88 96.88 
CA+ Eudra_g_it EPO CA+ Eudra_gJt EPO 
20 498967 15.24 76.19 20 541789 16.55 82.73 
60 1567546 46.523 77.54 76.34 60 1603494 47.59 79.32 80.61 
100 2498723 75.299 75.3 100 2647239 79.78 79.78 
Table 13 : Purity data of the microfluidized and recrystallized drug with the polymers - PVP, Eudragit EPO and Eudragit RD 100 
10.5 min 
11.6 min 
12.4 min 
Isomer B 
Complex 
Isomer A 
Figure 29: Chromatogram showing the peaks of isomers B and A, eluting at 
10.5 min and 11.6 min and the complex at 12.4 rnin 
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Figure 30: Solubility profile of the untreated drug and the physical mixture, micro fluidized and recrystallized drug with PVP 
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Figure 31: Solubility profile of the untreated drug and the physical mixture, micro fluidized and recrystallized drug with 
Eudragit EPO 
l.O 
°" 
1000 
900 
800 
700 
E 600 
Ci 
2. 
~ 500 
:c 
:I 
0 400 (/) 
I 
300 
200 
100 
0 
0 200 400 600 
---------.~~~~~~~~~~~~~~~~~~~~~~~~~~ 
800 
Time(min) 
1000 1200 1400 
---, 
1600 
Figure 32: Solubility profile of the untreated drug and the physical mixture, microfluidized and recrystallized drug with 
Eudragit RDlOO 
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Figure 33 : XRD scan of the untreated and recrystallized cefuroxime axetil with the polymers (A: untreated, B: CA + PVP, 
C: CA + Eudragit RD 100, D: CA+ Eudragit EPO) 
( 
RD 100 are partially amorphous with varying degrees of crystallinity. The DSC 
scans show an absence of the endotherm at 123 °C in all the samples, while the 
endotherm at 173 °C is absent in the sample containing Eudragit EPO. The 
other two samples show the presence of the higher melting endotherm but the 
heat of fusion is lower than that of the pure sample indicating disruption of the 
crystal structure of isomer A (Table 11). Heat of fusion (.6.S f = .6.Hf I Tm) has 
been used as an indication of disruption or disorder induced by additives or 
impurities 16• The X-ray diffraction data for the microfluidized - PVP, Eudragit 
EPO, and Eudragit RDlOO samples are shown in Figure 34. All the samples 
subjected to microfluidization are converted to the totally amorphous form as 
seen from the XRD scans and confirmed from the DSC data, indicating the 
absence of both the melting endotherms. 
The samples prepared with Eudragit EPO show the lowest solubility, which 
could be attributed to the formation of the complex between the cationic 
polymer and the anionic drug, detected on the chromatogram as a third peak (at 
- 12.5 min). The recrystallization process and polymer combinations involving 
PVP and Eudragit RD 100 do not render the drug amorphous, but a high degree 
of crystal disruption may be the cause of the enhanced solubility. We do notice, 
however, that one of the isomers is converted to the amorphous form while the 
other is in a partially crystalline state. The heat of fusion of the partially 
crystalline isomer (A) is also reduced, as seen in Table 11 . 
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Figure 34: XRD scan of the untreated and microfluidized cefuroxime axetil with the polymers (A: untreated, B: CA+ PVP, 
C: CA+ Eudragit RDlOO, D: CA + Eudragit EPO) 
A microscopic analysis of all the processed mixtures shows a loss of the needle 
shaped crystalline structure of the samples, similar to the ones shown before 
(Figures 22 and 23). 
Table 14 lists the yields for the two processes along with the polymers. It was 
noticed that the process of microfluidization yielded very low quantities of the 
sample (~ 70%), whereas the recrystallization process gave significantly higher 
yields. Based on the statistical analysis along with the process yields, the 
recrystallized CA-PVP combination was selected for the preparation of the 
tablets. 
2.5 Statistical Analysis 
A two-factor factorial design is used to study the effect of the different processes 
and polymers on the solubility of the drug. In this study, we have a 3 x 4 
factorial design, that is, we have 2 factors, one with 3 levels and the other with 4 
levels. The two factors are polymer (C 1) and process (C2), with 4 and 3 levels, 
respectively. The two independent variables, their levels and their values are 
summarized in Table 15. Therefore the number of treatment groups we have is 
3 x 4 = 12 groups (Table 16). Data for each representative group was generated 
in triplicates, hence we have 36 observations, as listed in Table 17. Solubility 
was the response parameter. All the statistical and regression analysis 
procedures on the response parameters were performed using Minitab® 
software package. Statistical analysis carried out included analysis of variance 
(ANOV A) to determine the significance of each independent variable (process, 
100 
,_. 
0 
Method Yield % Yield 
(mg) 
Recrystallization 
CA - without polymer 850 I 900 94.44 
CA-with PVP 962 I 1000 96.2 
CA - with Eudragit EPO 938 I 1000 93.8 
CA - with Eudragit RD100 944 I 1000 94.4 
Microfluidization 
CA - without polymer 674 I 900 74.8 
CA-with PVP 703 I 1000 70.3 
CA - with Eudragit EPO 673 I 1000 67.3 
CA - with Eudragit RD100 695 I 1000 69.5 
Table 14: Yields for the different process-polymer combinations are shown (reported values are the average 
of three replicates) 
Factor Type Levels Values 
Polymer Fixed 
Process Fixed 
4 
3 
Polymer 
1 No polymer 
2 PVP 
3 Eudragit EPO 
4 Eudragit RD 100 
1234 
123 
Process 
1 No process 
2 Microfluidization 
3 Recrystallization 
Table 15: List of factors and levels used in ANOV A analysis of effects 
on solubility 
102 
( 
No. C1 C2 
Polymer Process 
1 1 1 
2 1 2 
3 1 3 
4 2 1 
5 2 2 
6 2 3 
7 3 1 
8 3 2 
9 3 3 
10 4 1 
11 4 2 
12 4 3 
Table 16: 3 x 4 (2-factor) full factorial design 
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C1 C2 
Polymer Process 
1 1 
1 1 
1 1 
1 2 
1 2 
1 2 
1 3 
1 3 
1 3 
2 1 
2 1 
2 1 
2 2 
2 2 
2 2 
2 3 
2 3 
2 3 
3 1 
3 1 
3 1 
3 2 
3 2 
3 2 
3 3 
3 3 
3 3 
4 1 
4 1 
4 1 
4 2 
4 2 
4 2 
4 3 
4 3 
4 3 
C3 
Solubility 
(ug/ml} 
353.97 
352 .91 
357.02 
882.26 
859.85 
843.40 
900.14 
949.69 
918.86 
402.03 
398.57 
395.14 
887.52 
891 .77 
877.80 
859.48 
858.90 
860.15 
380.15 
365.41 
373.81 
641 .89 
632.44 
654.62 
672.85 
685.17 
681.95 
391.08 
359.43 
374.91 
652.35 
657.13 
664.86 
627.90 
620.82 
623.54 
104 
Polymer 
1 - No polymer 
2 - PVP 
3 - Eudragit EPO 
4 - Eudragit RD 100 
Process 
1 - No process 
2 - Microfluidization 
3 - Recrystallization 
Table 17: Data for each representative 
group of factors and response 
( polymer), two-way interactions (process-polymer), mam effect plots and 
interaction plots 17 . The general linear model used for the experimental design 
was: 
The ANOV A table (Table 18) summarizes the statistical analyses conducted. 
From the table we can see that the P-values for the polymer, process, and the 
polymer-process interactions are lower than the a-value (0.05). Hence we can 
conclude that these three factors have a significant effect on the solubility of the 
drug. The main effects plot for process shown in Figure 35 indicates that both 
the processes (microfluidization or recrystallization) show an almost equivalent 
increase in solubility as seen from points 2 and 3 in the graph. From the 
interactions plot, Figure 36, it is observed that the combination of PVP with 
either of the processes (represented as line •- - - - - •) would be a good choice 
for improving solubility. As seen from the graph, process 2 (microfluidization) 
and 3 (recrystallization) show a significantly higher solubility, thus making them 
a good choice for use in the preparation of tablets. The normal probability plot 
(Figure 37) follows an almost straight line, and hence the distribution is normal 
and the model used is adequate. 
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General Linear Model: Solubility versus Polymer, Process 
Factor Type Levels Values 
Polymer fixed 4 1 2 3 4 
Process fixed 3 1 2 3 
Analysis of Variance for Solubility, using Adjusted SS for Tests 
Source 
Polymer 
Process 
Polymer* Process 
Error 
1 Total 
Polymer: 4 levels 
1 - no polymer 
2-PVP 
3 - Eud EPO 
4 - Eud RDlOO 
DF 
3 
2 
6 
24 
35 
Seq SS 
216859 
1226825 
119052 
3194 
1565930 
Process: 3 levels 
1 - no process 
2 - microfluidization 
3 - recrystallization 
Adj SS 
216859 
1226825 
119052 
3194 
Table 18: ANOVA table summarizing the statistical analyses 
Adj MS F p 
72286 543.12 0.000 
613412 4608.85 0.000 
19842 149.08 0.000 
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Main Effects Plot - LS Means for Solubility 
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Figure 35: Main effects plot for polymer and process 
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Figure 36: Interaction plot showing effect of various process-polymer combinations on solubility (polymer: 1-no polymer, 
2-PVP, 3-Eudragit EPO, 4-Eudragit RDlOO) 
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Figure 37: Normal probability plot following an almost normal or linear distribution 
( 2.6 Tablet Preparation and Dissolution Studies 
Drug absorption from a solid dosage form after oral administration depends on 
the release of the drug substance from the drug product, the dissolution or 
solubilization of the drug under physiological conditions, and the permeability 
of the gastrointestinal tract. Because of the critical nature of the first two of 
these steps, in vitro dissolution may be relevant in the prediction of in vivo 
performance18. Based on the statistical analysis of the data obtained from the 
solubility studies of the microfluidized and recrystallized drug-polymer 
combinations, it was noticed that the drug in combination with PVP and either 
of the processes rendered the drug more soluble. However, due to the low yield 
of the microfluidization process, the recrystallized drug-PVP combination has 
been used in preparation of the tablets (or compacts) for dissolution studies. The 
dissolution studies have been performed to ensure that the dissolution profile of 
the treated drug, in its dosage form, follows USP requirements . The 
recrystallized drug-PVP combination is also a good choice for the tablet 
formulation as it not in a totally amorphous form and the stability issues related 
to the amorphous drug are minimized, when the drug used is in a partially 
crystalline state. Also the presence of a small amount of polymer acts as 
crystallization inhibitor, preventing the reconversion of the amorphous form of 
the drug to its crystalline form. This is evident from the solubility profiles of the 
treated drug in the absence and presence of polymers, as seen earlier. As the 
solubility profiles indicated, the stability of this form in the solution state is very 
high; and the drug would be expected to maintain a high level of solubility over 
110 
( the duration of the study. Tablets prepared with the untreated drug serve as a 
blank. The marketed formulation of cefuroxime axetil, Ceftin Tablets®, 
manufactured by GlaxoSmithKline, was used as a reference for comparison 
purposes. The tablets prepared with the drug and the drug-PVP combinations 
contain similar excipients as the marketed formulation. 
2.6.1 Preparation of Tablets (or compacts): 
Tablets of cefuroxime axetil were prepared containing an equivalent of 250 mg 
of cefuroxime. The total weight of the tablet was fixed at 4 70 mg (based on the 
marketed formulation). In addition to the drug, the tablets contained the inactive 
ingredients colloidal silicon dioxide, croscarmellose sodium (Ac-Di-Sol), 
microcrystalline cellulose (A vicel), hydroxypropyl methylcellulose, and sodium 
lauryl sulfate. Tablets were prepared with the untreated drug as well as the 
recrystallized drug-PVP mixture. In the latter formulation HPMC was omitted 
due to the presence of PVP. All the powders were sieved through a sieve of 
mesh size 40. The components of the formulation were mixed according to the 
formulation (Table 19) for 15 minutes on the rotary shaker. Tablets were 
prepared by direct compaction on the Carver press at a compression pressure of 
1000 lbs. A batch of 20 tablets was prepared for each of the formulations. 
2.6.2 Dissolution studies: 
USP apparatus 2 was used. The apparatus was set to 55 rpm. The temperature 
of the water bath was set to 37 ± 0.5 °C. Dissolution medium used was 0.07 N 
HCI. For the dissolution studies, 900 ml of the dissolution medium was filled in 
the dissolution flasks and the system was allowed to equilibrate for 30 minutes. 
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Formulation Ingredients Composition Composition 
(%) (mg/tablet) 
A Cefuroxime axetil 64.255 302 
(untreated HPMC 0.25 1.175 
CA) MCC 20 94 
Croscarmellose sodium 8.995 42.275 
SLS 6 28.2 
Colloidal silica 0.5 2.35 
B Cefuroxime axetil + PVP 72.341 340 
(CA+ PVP) MCC 13.617 64 
Croscarmellose sodium 8.569 40.275 
SLS 5.149 24.2 
Colloidal silica 0.5 2.35 
Table 19: Formulations A and B for tablet preparation 
-, 
Batch of 20 tablets 
(gm) 
6.04 
0.0235 
1.88 
0.8455 
0.564 
0.047 
6.8 
1.28 
0.8055 
0.484 
0.047 
( Six tablets weighing approximately 470 mg were selected and placed in each of 
the six dissolution flasks. Sampling was performed at predetermined time 
points, namely 5, 15, 30, 45, 60, 90 and 120 minutes. At each time interval, 1 
ml of the sample was withdrawn from the dissolution flask and replaced by 
equivalent amount of fresh dissolution medium at the same temperature. The 
samples were filtered by centrifugation, 0.5 ml of the filtrate was diluted with 
0.5 ml of the mobile phase and the samples were analyzed by HPLC. 
2.7 Results and Discussion: 
The tablets prepared were tested for their drug content and their dissolution 
profiles were determined based on the above method. The USP limits for 
content uniformity are as follows, "Cefuroxime axetil tablets should contain the 
equivalent of not less than 90.0 percent and not more 110.0 percent of the 
labeled amount of cefuroxime". Six (6) tablets were used to determine the 
amount of drug present in the tablets. The results for the drug content in the 
tablets are tabulated in Table 20. As the results indicate, Formulation A 
contains an average of 97% and Formulation B contains an average of 99% of 
cefuroxime. Hence, both the formulations lie within the USP limits for drug 
content. The limits for the USP content uniformity have been used as a basis for 
determining the amount of drug in both the formulations. The dissolution 
profiles of the tablets prepared from the untreated drug and the drug-PVP 
mixture are shown in Figure 38. For dissolution, the USP limits state that "not 
less than 60% of the labeled amount of cefuroxime is dissolved in 15 minutes, 
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Cefuroxime Axetil 
Formulation AUG AUG Concentration Concentration Concentration 
Isomer B Isomer A Isomer B Isomer A Total 
(mg/ml) (mg/ml) (mg/ml) 
x 
Formulation 3162192 599854 237.21 45.19 282.39 
A 3016117 767811 226.26 57.77 284.03 
(untreated 3063252 1020631 229.79 76.72 306.51 
CA) 3128591 651743 234.69 48.17 282.86 
3045763 857881 228.48 64.52 293.01 
3089162 1015047 231.74 76.30 308.04 
Formulation 2369873 1519100 177.83 114.08 291.91 
B 2675032 1447847 200.69 108.74 309.44 
(CA+ PVP) 2442159 1529541 183.25 114.86 298.11 
2514097 1607521 188.64 120.71 309.34 
2489156 1439513 186.77 108.11 294.88 
2513965 1481834 188.63 111 .29 299.92 
Table 20: Data for the drug content of the tablets for formulations A and B 
---.,. 
Cefuroxime 
Concentration Percent 
Total 
(mg/ml) (%) 
X*0.83 = Y l{_Y/2501*100 
234.37 93.75 
235.75 94.29 
254.41 101.76 
234.78 93.91 
243.19 97.28 
255.67 102.27 
Avera_g_e 97.21 
242.28 96.91 
256.83 102.73 
247.43 98.97 
256.76 102.70 
244.75 97.89 
248.93 99.57 
Avera_g_e 99.79 
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Figure 38: Dissolution profiles (in terms of concentration of cefuroxime axetil) of the tablets prepared from untreated drug 
(formulation A), drug-PVP mixture (formulation B) and the marketed formulation (Ceftin®) 
( and not less than 75% is dissolved in 45 minutes". The tablets prepared from 
the drug-PVP mixture show a dissolution profile comparable to that of the 
marketed formulation (Figure 38). The dissolution profiles in Figure 38 are 
shown in terms of the concentration of cefuroxime axetil determined over time, 
whereas in Figure 39, the dissolution profiles are expressed in terms of the 
percent cefuroxime dissolved over time. The data for the dissolution profiles of 
the two formulations (untreated drug and drug-PVP combination) are shown in 
Table 21 . As seen from this data, tablets of formulation A show substantially 
lower concentrations of cefuroxime at 15 minutes (109.619 µg/ml) and 45 
minutes (121.876 µg/ml) . These concentrations correspond to 43.847% (at 15 
minutes) and 48.75% (at 45 minutes), and are well below the USP requirements 
stated above. The tablets prepared from the drug-PVP mixture, on the other 
hand, show a remarkable increase in concentration at the 15 minute (153.746 
µg/ml) and 45 minute (212.582 µg/ml) time points. These tablets conform to the 
USP dissolution requirements, in that, 61 % dissolves in 15 minutes and 85% in 
45 minutes. 
2.8 Summary: 
The modification of a crystalline drug to its amorphous or partially crystalline 
form has a significant effect on the solubility of the drug, as evident from this 
study. The new application of microfluidization, as a means of modifying the 
crystal structure, has been successfully evaluated. However, studies with other 
116 
........ 
........ 
-...l 
110 
100 
90 
80 
70 
"O 
Q) 
> 60 0 l---0-C~ -+-CP.PVP -t:r-Ceftin 
I/) 
I/) 
0 50 
~ 0 
I 40 
I 
30 
20 
10 
0 ~ -··r-
0 20 40 60 80 100 120 140 
Time (min) 
Figure 39: Dissolution profiles (in terms of% dissolved of cefuroxime) of the tablets prepared from untreated drug 
(formulation A), drug-PVP mixture (formulation B) and the marketed formulation (Ceftin®) 
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Formulation Time Concentration Concentration Percent 
(min) (Cefuroxime (Cefuroxime) (Cefuroxime) 
axetil) X X*0.83 = Y (Y/250)*100 
(ug/ml) (ug/ml) (%) 
Formulation 0 0 0 0 
A 5 109.53 90.91 36.37 
(untreated 15 132.07 109.62 43.85 
CA) 30 143.43 119.04 47.62 
45 146.84 121.88 48.75 
60 153.35 127.28 50.91 
120 151.72 125.93 50.37 
Formulation 0 0 0 0 
B 5 150.07 124.56 49.82 
CA+ PVP) 15 185.24 153.75 61.49 
30 242.19 201.02 80.41 
45 256.12 212.58 85.03 
60 276.31 229.34 91.74 
120 284.38 236.04 94.41 
Table 21: Data for the dissolution of tablets for formulations A and B 
drugs need to be carried out to substantiate the results of this investigation and to 
emphasize the importance of this approach towards the development of a more 
stable amorphous form. 
The results of this investigation can be summarized as follows: 
1. Microfluidization can be effectively used as a means of converting a 
crystalline drug to its amorphous form. 
2. Polymers used in this study efficiently serve the purposes they were 
employed for, namely, assisting in improving the solubility of the drug, 
acting as impurities to destabilize the rigid crystal structure, and as 
crystallization inhibitors, preventing reconversion of the amorphous drug 
to its crystalline form. 
3. Different process-polymer combinations show different effects on the 
individual isomers of the drug. 
4. PVP was the better polymer among the three polymers used in this study. 
5. Tablets/compacts prepared from the drug-polymer mixture exhibit 
dissolution profiles in accordance to the USP limits. 
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